The pancreas consists of two main compartments, the exocrine and endocrine tissue, both with distinct functions. Exocrine tissue consists predominantly of acinar cells that release digestive enzymes into the duodenum via a ductal system, making up most of the cell mass found in the organ. The pancreas also contains endocrine cells that are organized together into highly vascularized cell clusters called the islets of Langerhans. Endocrine cells within islets secret hormones that exquisitely regulate and maintain blood sugar levels within a tight physiological range. Representing only about ~1–2% of the organ tissue, the main endocrine cells are insulin-producing β-cells, glucagon-producing α-cells, somatostatin-producing δ-cells, polypeptide-producing PP cells, and ghrelin-producing ε-cells
[1]. Out of all endocrine cells, only β-cells express and secrete insulin in response to elevations in blood glucose levels. β-cell dysfunction or loss is key in contributing toward the development of diabetes, and much research has focused on this fascinating cell type.
Diabetes presents as two major subtypes. In both, the inadequate release of insulin results in hyperglycemia that can be life-threatening. The most common diabetes form, type 2 diabetes (T2D), affecting 462 million people globally, is characterized by the insulin resistance of peripheral tissues and (subsequent) β-cell dysfunction, exhaustion, and loss
[2]. In type 1 diabetes (T1D), the patient’s own insulin-producing β-cells are specifically destroyed through an autoimmune-mediated attack predominantly of T-cells, resulting in insulin deficiency. Type 1 diabetes (T1D) is a chronic condition that affects 1 in 500 Americans by the age of 15
[3]. Current treatment for both T1D and late-stage T2D consists of injecting endogenous insulin. Exogenous insulin replacement therapy falls short of recapitulating the exact physiological function of a β-cell, and patients are susceptible to acute and long-term complications
[4][5][6]. Hypoglycemic conditions, induced by injecting too much insulin, can result in a life-threatening coma and are a constant risk for patients living with T1D and a practical cure that would alleviate the risks and concerns of current insulin therapy is desperately needed.
2. Current and Potential Cell Replacement Strategies for T1D Patients
Islet Transplantation to Restore β-Cell Mass
A proof of principal for a potential practical cure has been shown with the establishment of the Edmond protocol in 2000. In this protocol, isolated allogenic cadaveric islets are infused in the portal vein of long-standing T1D patients that receive non-steroid immunosuppression
[7][8]. Importantly, islet recipients achieve on average ~35 months of insulin independence
[9]. Subsequently, islet transplantation was often performed in conjunction with kidney transplantation
[10]. However, there are several challenges associated with this procedure that prevent it from becoming widely accessible for patients. A major drawback with islet transplantation is the limited availability of high-purity isolated human cadaveric donor islet material. This is required to restore euglycemia in patients. Typically, each patient receives 10,000 islet equivalents (IEQs) per kilogram of body weight, an amount that usually needs to be extracted from two donor pancreases. In addition, initial clinical trials showed some patients requiring multiple islet infusions throughout the study, further highlighting the need for an abundant source of functional insulin-producing cells. The chronic immune suppression of patients, especially in children and adolescents, is problematic due to long-term complications, including severe and chronic infections and malignancy. In addition, studies have shown that immune suppressive agents impair β-cell function and survival using animal models
[11][12]. Indeed, functional cadaveric islet grafts are frequently lost within 2–5 years due to recurring autoimmunity, side effects of immunosuppressants, and other unknown mechanisms
[9][13]. The lack of sufficient donor islets has prompted the search for alternative and abundant sources of functional β(-like) cells for replacement therapy purposes, and much progress has been made using different approaches.
Since porcine insulin has been shown to be physiologically well-matched to humans, the xenotransplantation of porcine islets has been considered an effective strategy to provide adequate amounts of islet material to treat T1D patients. However, immunological responses, such as instant blood-mediated inflammatory reaction (IBMIR)
[14][15][16], hyperacute, and cellular rejection, remain major hurdles to overcome and improve porcine islet survival
[17][18][19][20][21]. Therefore, several strategies have been explored to overcome immune complications in this setting. The development of genetically modified pigs lacking the expression of certain surface proteins that play key roles in immune rejection upon porcine islet transplantation demonstrates promising results in improving porcine islet survival through combating IBMIR and hyperacute rejection. Preclinical studies also revealed that the blockade of co-stimulatory cell surface molecules suppresses T cell activation, hampers cellular rejection, and improves islet survival in vivo. With no evidence of porcine endogenous retrovirus (PERV) transmission, clinical studies of porcine islet xenotransplantation in T1D patients showed initial successes; however, most recipients failed to maintain long-term normal glycemic levels. Encapsulating pig islets has been suggested as effective in reducing xenogeneic immune rejection and prolonging graft survival and was tested in two clinical studies in T1D patients but showed only minimal reduction in their daily insulin needs
[22][23][24][25][26].
3. Alternative Approaches to Increase Functional β-Cell Mass
Other strategies have aimed at inducing β-cell replication or neogenesis via the transdifferentiation of pancreatic non-β cells to replenish the β-cell mass. Recently, DYRK1A inhibition in conjugation with other pathway manipulations has been shown to be effective in inducing increased β-cell proliferation
[27][28][29][30][31][32]. If safe β-cell-specific delivery modalities can be identified, inducing the proliferation of remaining β-cells in diabetic patients might provide a viable therapeutic strategy
[33].
Transdifferentiation refers to the change in functional cell phenotype of a differentiated cell into another rather than the differentiation of a less specialized stem cell into a functional cell type. Pancreatic duct ligation (PDL) has been shown to promote β-cell transdifferentiation from ductal, acinar, and alpha cells in mice
[34][35][36][37], although some observations could not be repeated in another study
[38]. Similarly, the overexpression of
MafA,
Pdx1, and
Ngn3 can trigger β-cell transdifferentiation predominantly from mouse acinar cells in vivo
[39]. Recently, a group induced alpha cell transdifferentiation into β-cells in vivo by infusing adeno-associated viruses carrying
Pdx1 and
MafA into the pancreatic duct of NOD mice
[40]. However, such experimental strategies, while carrying the potential for endogenous β-cell repopulation in T1D patients, are awaiting translation to human systems and/or clinical settings.
4. Stem-Cell-Derived β-Cells as an Abundant Cell Source
One attractive approach that has advanced rapidly and shows tremendous potential as an abundant source of functional insulin-producing cells for clinical use is the direct differentiation of human pluripotent stem cells (hPSCs) into stem cell-derived β-like cells (sBCs)
[41][42][43][44]. Mouse development studies have identified critical transcription factors and signaling events during pancreas organogenesis, and subsequent work defined the necessary culture conditions to mimic key development stages to direct the differentiation of sBC from pluripotent stem cells
[45][46][47][48]. Specifically, several groups focused their efforts on utilizing recombinant proteins and small molecules to generate subsequent cell types resulting in pancreatic cells: definitive endoderm generation
[49][50], posterior gut specification
[50][51][52][53], formation of pancreatic bipotent progenitors
[54][55][56], and endocrine differentiation
[41][42][43][50][57]. Although sBCs generated with early protocols were glucose-responsive, cells still displayed features of immature, fetal-like β-cells, and thus performed poorly in dynamic glucose-stimulated insulin secretion (dGSIS) perifusion assays. Several methods, such as the manipulation of key signaling pathways
[58][59][60], media composition and in vitro culture extension
[61][62], and the use of surface markers and fluorescence-activated cell sorting (FACS) to enrich reaggregated sBCs resulted in a more mature β-cell phenotype that closely resembles primary adult islets
[22][44][62][63][64]. Clear criteria defining a mature, functional β-cell that allows distinction from β-cell surrogates has recently been discussed in detail elsewhere
[65]. Interestingly, sBC maturation also seems to be accomplished upon transplantation, which in return restored euglycemia and reversed diabetes in preclinical mouse models
[41][42][43][66][67]. However, the early events taking place during the immediate engraftment of sBC have not been studied in detail. A considerable body of work has shown that the majority of functional β-cell mass is lost from human islets upon engraftment, suggesting that such drastic effects may also apply to sBCs due to unknown underlying cellular and molecular mechanisms
[68]. Potential mechanisms that might occur are: (i) cell death, (ii) dedifferentiation, and (iii) transdifferentiation (
Figure 1). Recent work identified distinct human β-cell subpopulations in sBC and human islets in vitro and provided the possibility of (iv) β-subtype interconversion upon engraftment as an additional mechanism. Hence, there is a critical knowledge gap in the research field concerning the fate of sBC upon engraftment. Expanding the knowledge of the contributing mechanisms would expedite the progress in promoting the current approaches of delivering sBC as an effective cell replacement therapy for T1D patients. In addition, sBC cell therapy might represent an attractive treatment modality for T2D patients due to the absence of reoccurring autoimmunity if allogeneic rejection can be avoided in a localized manner.
Figure 1. Reported and potential molecular and cellular mechanisms driving human pancreatic β-cell loss upon transplantation.
5. Engrafted β-Cell Loss via Cell Death
Classically, the main mechanism associated with islet cell death in vitro and in vivo is apoptosis. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) has shown that a considerable proportion of isolated human islets harvested from donor pancreases are lost in vitro within 5 days of culture due to apoptosis
[69]. The high propensity of β-cells to undergo apoptosis within islet preparations might be due to the increased metabolic rate that is not met under cell culture conditions. Later studies determined the caspase cascade as the major intrinsic mediator of apoptosis in cultured islets after being exposed to toxic levels of glucose
[70]. Glucotoxicity downregulated BCL-2 (anti-apoptotic protein) expression in isolated islets, which acts as an intrinsic signal to activate caspase-associated apoptosis
[71][72]. Similarly, after 24 h of transplantation, TUNEL staining showed that approximately a quarter of all β-cells in human islets engrafted in the kidney capsule of immunodeficient mice are lost due to apoptosis
[73]. Overall, although the exact mechanisms contributing to primary β-cell death upon transplantation are poorly understood, the current literature predominantly attributes the observed loss to ischemia and nutrient deprivation. Mediated by endothelial cells, in situ, pancreatic islets are highly vascularized and are under a continuous supply of oxygen and nutrients, ensuring optimal function. However, this supply is lost during the islet isolation process, which involves the use of digestive enzymes and mechanical force to separate the islets from the native organ
[74]. Due to loss of blood flow and imperfect culturing conditions, endothelial cells, which are critical in providing cellular matrix proteins that fine-tune the function of β-cells, eventually die in vitro
[75]. Since blood flow is abolished after isolation, islets are under an acute nutrient deficiency and exposed to oxidative stress mediated by hypoxia. Isolated islets depend on passive nutrition diffusion to satisfy the activities of the highly metabolic β-cells. Thus, culture conditions are insufficient in supplying uniform O
2 levels to all β-cells, especially cells located at the core of the islet, negatively effecting β-cell survival in vitro, with necrotic cores present, especially in larger islets due to low oxygen accessibility
[76][77][78]. Similarly transplanted human and rodent islets have been shown to have reduced graft oxygen tension in the initial stages of engraftment and to suffer a drastic loss of β-cells in vivo
[79][80][81][82][83][84]. Therefore, several in vitro pre-transplant priming methods have been adopted to improve islet survival in transplants, such as oxygenation treatment, culture in hyperoxic conditions, and modulation of seeding density; however, these strategies have failed to be exceedingly successful
[85][86][87]. Further mechanistic analysis revealed several signaling pathways, such as anaerobic glycolysis and hypoxia-inducible factor (HIF)-related pathways, to be associated with β-cell survival under hypoxic conditions; however, further investigation is required
[84][88][89][90][91][92][93]. Finally, other necrotic-regulated mechanisms such as pyroptosis
[94][95], ferroptosis
[96][97][98][99][100][101], and necroptosis
[102][103][104][105][106][107] have been implicated to contribute toward β-cell death during islet isolation, culture, and transplantation; however, these mechanisms have not been comprehensively elucidated as of yet.
Most in vivo sBC studies have focused on the metabolic action and long-term therapeutic capacity of engrafted, surviving cells using preclinical animals starting at 3–4 weeks post-transplantation when grafts are fully vascularized. However, most studies have largely neglected the early phase of sBC transplantation. In a recent study, sBCs constitutively expressing luciferase were transplanted subcutaneously or under the kidney capsule of immunodeficient mice, and total graft mass was quantified using bioluminescence
[68]. As expected, on the day of transplantation, robust expression of luciferase was detected; however, 7 days post-transplant, this expression was significantly reduced in both sites, indicating substantial graft loss. In addition, the hPSC cell line employed also contains a GFP reporter driven by the insulin promoter, allowing quantification of sBCs before and after transplant. Flow cytometry analysis revealed that approximately 70% of sBCs were lost, while the total graft was only 50% reduced within the first 7 days of engraftment, indicating a preferential loss of sBCs compared to other cells present. The main drivers of graft loss are considered to be ischemia-induced hypoxia and nutrition deprivation. Amino acid supplementation and adjusting the physiological oxygen levels to 5% in culture improved sBC graft survival significantly. In situ, pancreatic islets are abundantly vascularized with a continuous supply of oxygen and nutrients; therefore, this study further highlights the importance of vascularization to sBC survival and function in vivo. Pepper and colleagues showed the pre-vascularization of the subcutaneous site followed by the transplantation of pancreatic endoderm (PEC) cells improved stem cell-derived β-cell functionality and survival in vivo, providing further evidence for the notion that appropriate vascularization is critical for β-cell survival and function
[108]. Several groups focused on engrafting sBCs that incorporate endothelial cells alone or in combination with mesenchymal cells
[109][110][111][112][113]. In a recent elegant study, micro-vessels isolated from adipose tissue have been shown to improve and accelerate the vascularization of sBC grafts, as well as their survival and function in vivo
[114]. Finally, using oxygen-generating biomaterials shows promising results to improve islet survival in vivo that could be applied to future sBC engraftments
[109][113][115][116][117][118][119]. Altogether, the literature has provided data suggesting hypoxia and nutrient deprivation as two key contributors to sBC graft decline that can be mitigated by providing better engraftment solutions. Understanding what distinguishes sBCs that survive the first week of engraftment from sBCs that are lost during this period could provide additional means to preserve total functional graft mass.